Anti-tumor necrosis factor (TNF) agents can also be administered systemically to address SIJ pain, but their use is recommended only under specific conditions, such as persistent high disease activity, elevated CRP levels, or positive imaging for sacroiliitis [3]. This evidence concerns the gene TNF and Sacroiliac arthritis.